Noninvasive cardiac mapping company CardioInsight Technologies has raised a $7.5 million series C round of investment.
CardioInsight will use the new funding to push forward on European commercialization efforts and clinical studies aimed at obtaining U.S. regulatory clearance, according to a statement from the Cleveland-based company.
MedCity News reported today that CardioInsight is in discussions with the U.S. Food and Drug Administration about a regulatory path for its ECVUE electrocardiographic mapping system. It’s likely that the company will need to perform a U.S. clinical study before obtaining FDA clearance.
CEO Steve Arless declined to identify the investors in the latest round and instead said it was a combination of “old and new” investors.
When the company raised its $6 million series B round two years ago, it identified the investors as Draper Triangle Ventures, Case Technology Ventures and Dr. Michel Haissaguerre, a French electrophysiologist.
The company’s device gathers electrical information about the heart from an electrode vest placed on a patient’s body and combines that information with images from a CT scan to produce 3-D maps of the electrical activity of the heart. It’s used to help diagnose and treat electrical abnormalities of the heart, such as those associated with arrhythmia and heart failure.
CardioInsight has commercially installed its system at a total of three hospitals, which are located in the United Kingdom, France and Germany.
